查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018439

子宮肌瘤治療器械市場：按產品類型、技術、最終用戶和分銷管道分類－2026-2032年全球預測

Uterine Fibroid Treatment Device Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，子宮肌瘤治療設備市場價值將達到 6.842 億美元，到 2026 年將成長至 7.5751 億美元，到 2032 年將達到 14.9779 億美元，年複合成長率為 11.84%。

主要市場統計數據
基準年 2025 6.842億美元
預計年份：2026年 7.5751億美元
預測年份 2032 1,497,790,000 美元
複合年成長率 (%) 11.84%

關鍵的引言概述了臨床必要性、對病人歷程的影響以及正在重新定義子宮肌瘤治療設備引入的創新促進因素。

子宮肌瘤是最常見的良性婦科疾病之一，醫療設備的發展趨勢反映了醫療服務向微創、以病人為中心的方向轉變。臨床醫師越來越重視能夠緩解症狀、同時保留生育能力、縮短復原時間的治療方案。這些臨床需求，加上門診治療的必要性，正在推動降低手術全期風險和縮短住院時間的技術研發和改進。

臨床重點、患者期望和價值主導護理模式的轉變，正在如何重塑子宮肌瘤治療技術的競爭格局？

受臨床需求、技術創新和醫療服務模式演變的驅動，用於治療子宮肌瘤的醫療設備市場發生了翻天覆地的變化。微創手術因其安全性和有效性日益凸顯，與傳統手術相比更具優勢，因而越來越受歡迎。能量治療方法和影像導引系統的創新拓展了適應症範圍，並實現了門診手術，患者術後恢復更快，併發症風險更低。

本研究評估了美國於 2025 年徵收的關稅對醫療設備的採購、定價和打入市場策略的連鎖營運和商業影響。

2025年推出的關稅政策和貿易措施對美國醫療設備供應鏈和商業化策略產生了多方面的影響。部分零件和成品進口關稅的提高迫使製造商和經銷商重新評估籌資策略，盡可能優先考慮在地採購，並與供應商重新談判合約以緩解成本壓力。這些調整導致了一系列營運變革，包括重新審視庫存管理以及調整產品上市的預期前置作業時間。

透過有針對性的細分洞察，揭示產品類型、技術、醫療保健環境和分銷管道的交集，有助於塑造臨床應用和商業性重點。

細分市場趨勢深入分析了不同醫療設備類型和技術平台下的臨床實踐和購買行為。基於產品類型，市場分析涵蓋高強度聚焦超音波（HIFU）、子宮切除術、子宮肌瘤切除術、射頻消融術和子宮動脈栓塞術。子宮切除術進一步分為開放式、腹腔鏡式和陰式三種方法，而子宮肌瘤切除術則分為子宮鏡、腹腔鏡式和開放性手術方法。每種產品路徑都針對不同的臨床場景和患者偏好，對於符合條件的患者而言，微創方案正日益受到青睞。

影響美洲、歐洲、中東和非洲以及亞太地區醫療設備引進和打入市場策略的關鍵區域趨勢和製度因素。

區域趨勢對子宮肌瘤治療的監管、臨床和商業性路徑產生不同的影響，進而影響產品規劃和市場准入。在美洲，專業臨床中心的集中、完善的門診基礎設施以及活躍的臨床試驗活動，有利於創新微創醫療設備的早期應用。然而，支付方的複雜性和區域報銷體系的差異，使得制定針對具體情況的實證策略勢在必行。

深入了解競爭行為、創新策略和夥伴關係模式，這些將決定哪些公司能在不斷發展的子宮肌瘤治療設備生態系統中取得成功。

競爭格局由成熟的手術平台製造商、新興的能量型醫療設備創新者和專業服務供應商組成，所有這些因素共同影響臨床選擇和採購決策。主要企業致力於拓展適應症、加強與影像技術的整合，並開發適用於多種婦科應用的模組化平台。與此同時，小規模、更靈活的公司正透過專注於諸如改進能量傳輸技術、一次性器械和最佳化門診工作流程等細分領域的創新，在與規模更大、更成熟的廠商的競爭中站穩腳跟。

為醫療設備製造商和相關人員提供實用建議，以加快採用速度、降低供應鏈風險，並使證據與支付者和臨床醫生的優先事項保持一致。

產業領導企業應採取多管齊下的策略，在臨床證據的累積與商業性彈性之間取得平衡。優先進行積極主動、切實可行的臨床研究，重點關注患者相關結局，符合支付方的價值框架，並支持有利的保險覆蓋決策。同時，投資於培訓計畫和流程支持，以減少外科醫生、介入醫生和門診護理團隊在採用新技術方面的障礙，從而加速技術在門診環境中的應用。

調查方法結合了專家訪談、監管審查和證據三角檢驗，清晰透明，並採用混合方法，以確保嚴謹且可操作的見解。

本研究採用混合方法，結合對臨床醫生、採購經理和支付方的定性訪談，以及對監管指南、臨床文獻和政策趨勢的二次審查。該方法強調“三角驗證”，即將專家意見與程序指南和公開的臨床證據進行比對，以識別通用主題和差異。透過交叉引用程序趨勢和技術採納徵兆，確保資料的有效性，從而確保內部一致性和可操作性。

結論強調了臨床創新、供應鏈韌性和證據一致性如何決定子宮肌瘤治療設備市場的長期成功。

總之，子宮肌瘤治療器材領域正朝著微創、以價值為導向的治療路徑發展，優先考慮患者復健、生育力保護和醫療資源的有效利用。技術創新和手術流程的改進正在拓展治療選擇，這不僅為臨床醫生和採購者帶來了機遇，也帶來了挑戰。能夠將臨床證據的產生與切實可行的價值提案和靈活的商業策略結合的機構，將贏得市場。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：子宮肌瘤治療器械市場：依產品類型分類

  • 高強度聚焦超音波
  • 子宮切除術
    • 剖腹手術
    • 腹腔鏡
    • 陰道儀式
  • 子宮肌瘤切除術
    • 子宮鏡
    • 腹腔鏡
    • 剖腹手術
  • 射頻消融術
  • 子宮動脈栓塞術

第9章：子宮肌瘤治療器械市場：依技術分類

  • 冷凍消融術
  • 高強度聚焦超音波
  • 微波消融術
  • 射頻消融術

第10章：子宮肌瘤治療器械市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
  • 子宮肌瘤專科中心

第11章 子宮肌瘤治療器械市場：依通路分類

  • 離線
  • 線上

第12章 子宮肌瘤治療器械市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 子宮肌瘤治療器械市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 子宮肌瘤治療器械市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國子宮肌瘤治療器械市場

第16章：中國子宮肌瘤治療器械市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acessa Health Inc.
  • AngioDynamics, Inc.
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • CooperSurgical, Inc.
  • Gynesonics, Inc.
  • Hologic, Inc.
  • INSIGHTEC Ltd.
  • Karl Storz SE & Co. KG
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Minerva Surgical, Inc.
  • Olympus Corporation
  • Profound Medical Corp.
  • Richard Wolf GmbH
  • SonaCare Medical, LLC
  • Varian Medical Systems, Inc.
Product Code: MRR-0360AB17E12E

The Uterine Fibroid Treatment Device Market was valued at USD 684.20 million in 2025 and is projected to grow to USD 757.51 million in 2026, with a CAGR of 11.84%, reaching USD 1,497.79 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 684.20 million
Estimated Year [2026] USD 757.51 million
Forecast Year [2032] USD 1,497.79 million
CAGR (%) 11.84%

A focused introduction outlining clinical imperatives, patient journey influences, and innovation drivers redefining uterine fibroid treatment device adoption

Uterine fibroids represent one of the most common benign gynecologic conditions, and the evolving device landscape reflects a shift toward less invasive, patient-centered care. Clinicians increasingly prioritize procedures that deliver symptom relief while preserving fertility and reducing recovery time. These clinical imperatives, combined with patient demand for outpatient options, have catalyzed the development and refinement of technologies that mitigate perioperative risks and minimize hospital stays.

In parallel, technological advancements and procedural innovation have expanded the therapeutic toolkit available to physicians, creating a more nuanced decision matrix influenced by fibroid size, number, location, patient age, and reproductive goals. Regulatory pathways and reimbursement considerations further shape adoption, as stakeholders evaluate evidence generation strategies to support new indications and label expansions. Consequently, market participants must navigate a complex interplay of clinical evidence, device performance, and health-system economics to succeed in this dynamic environment.

How shifts in clinical priorities, patient expectations, and value-driven care models are reshaping the competitive dynamics of uterine fibroid treatment technologies

The landscape for uterine fibroid treatment devices has undergone transformative shifts driven by clinical priorities, technological innovation, and changing care delivery models. Minimally invasive procedures have gained traction as evidence accumulates on their safety and efficacy compared with traditional surgical approaches. Innovations in energy-based modalities and image-guided systems have expanded indications and enabled procedures to be performed in ambulatory settings with faster recovery and lower complication profiles.

Simultaneously, patient expectations have evolved; greater access to information and a preference for fertility-preserving options have led clinicians to reconsider historical default treatments. Health systems have responded by establishing specialized pathways and centers of excellence to concentrate expertise and improve outcomes. Moreover, payer scrutiny and value-based contracting have incentivized devices and procedures that demonstrate measurable improvements in short-term recovery and long-term quality of life. As a result, the competitive terrain favors manufacturers that pair robust clinical evidence with clear value propositions and scalable commercialization strategies.

Evaluating the cascading operational and commercial consequences of United States tariffs introduced in 2025 on device sourcing, pricing, and market access strategies

Tariff policies and trade actions introduced in 2025 have exerted a layered impact on medical device supply chains and commercialization strategies within the United States. Increased import duties on select components and finished devices compelled manufacturers and distributors to reassess sourcing strategies, prioritize localization where feasible, and renegotiate supplier contracts to mitigate cost pressures. These adjustments produced a cascade of operational changes, including inventory management revisions and altered lead-time assumptions for product launches.

Although clinical adoption decisions remain grounded in safety and efficacy, the added cost and logistical complexity have influenced pricing strategies and contract negotiations with health systems. In some cases, organizations accelerated plans for domestic manufacturing partnerships or sought alternative component suppliers in allied markets to preserve margin and maintain competitive pricing. Looking forward, manufacturers that integrate flexible supply chain architectures, transparent cost models, and proactive stakeholder communications will navigate tariff-driven disruptions more effectively and sustain access to the U.S. clinical market.

Targeted segmentation insights revealing where product types, technologies, care settings, and distribution channels intersect to shape clinical adoption and commercial focus

Segment-level dynamics offer a nuanced view of clinical practice and purchasing behavior across device types and technology platforms. Based on Product Type, market analysis considers High Intensity Focused Ultrasound, Hysterectomy, Myomectomy, Radiofrequency Ablation, and Uterine Artery Embolization, with Hysterectomy further categorized into Abdominal, Laparoscopic, and Vaginal approaches and Myomectomy divided into Hysteroscopic, Laparoscopic, and Open techniques. Each product pathway addresses distinct clinical scenarios and patient preferences, with less invasive options increasingly favored for suitable candidates.

Based on Technology, the field is examined through the lens of Cryoablation, High Intensity Focused Ultrasound, Microwave Ablation, and Radiofrequency Ablation, each offering different trade-offs in terms of tissue specificity, procedural duration, and imaging compatibility. Based on End User, the analysis spans Ambulatory Surgical Centers, Clinics, Hospitals, and Specialized Fibroid Centers, revealing how care setting influences device selection, procedural throughput, and reimbursement patterns. Based on Distribution Channel, considerations include Direct Sales, Distributors, and E Commerce, highlighting how channel strategy affects market reach, customer relationships, and adoption velocity. Integrating these segmentation layers clarifies where clinical unmet needs align with technological strengths and where commercial focus can yield the greatest strategic return.

Key regional dynamics and institutional factors across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence device adoption and market entry strategies

Regional dynamics influence regulatory, clinical, and commercial pathways for uterine fibroid treatments in distinct ways that affect product planning and market entry. In the Americas, a concentration of specialized clinical centers, extensive outpatient infrastructure, and robust clinical trial activity support early adoption of innovative, minimally invasive devices, while payer complexity and regional reimbursement variability require adaptive evidence strategies.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization efforts coexist with diverse public and private payer systems, creating both opportunities for centralized approvals and challenges in localized evidence generation. Adoption in this region often hinges on demonstrating cost-effectiveness within constrained health budgets. Asia-Pacific exhibits rapid infrastructure expansion, growing demand for fertility-preserving interventions, and increasingly sophisticated private healthcare networks; however, market entry strategies must account for varied regulatory timelines, local clinical practice patterns, and government-led initiatives to develop domestic manufacturing capabilities. Understanding these regional contours enables prioritization of regulatory pathways, clinical partnerships, and commercial investments that align with on-the-ground realities.

Insight into competitive behaviors, innovation strategies, and partnership models that determine which companies succeed in the evolving uterine fibroid device ecosystem

The competitive landscape comprises established surgical platform manufacturers, emerging energy-based device innovators, and specialized service providers that together shape clinical options and procurement decisions. Leading companies have concentrated on expanding procedural indications, enhancing imaging integration, and developing modular platforms that serve multiple gynecologic applications. At the same time, smaller, agile firms have focused on niche innovations-improvements in energy delivery, disposable instrumentation, and outpatient workflow optimization-that create entry points against larger incumbents.

Strategic partnerships between device makers and clinical networks have accelerated real-world evidence collection and facilitated rapid feedback loops to refine training and support. Additionally, companies that invest in comprehensive training curricula and digital support tools have seen higher procedure adoption and customer satisfaction. Competitive differentiation increasingly rests on the ability to demonstrate not just clinical efficacy, but also measurable reductions in procedural time, complication rates, and total episode-of-care burden, thereby appealing to both clinicians and value-conscious purchasers.

Actionable recommendations for device manufacturers and stakeholders to accelerate adoption, de-risk supply chains, and align evidence with payer and clinician priorities

Industry leaders should adopt a multi-pronged strategy that balances clinical evidence generation with commercial agility. Prioritize prospective, pragmatic clinical studies that address patient-relevant outcomes and align with payer value frameworks to support favorable coverage decisions. Simultaneously, invest in training programs and procedural support that lower the barrier to adoption among surgeons, interventionalists, and ambulatory care teams, thereby accelerating uptake in outpatient settings.

Operationally, diversify supply chains and consider nearshoring or multi-sourcing strategies to mitigate tariff- and logistics-related risks. Enhance commercial models by tailoring distribution approaches to account for the distinct needs of hospitals, ambulatory surgical centers, clinics, and specialized fibroid centers, while leveraging digital channels to increase market reach. Finally, cultivate collaborations with key opinion leaders, patient advocacy groups, and payers to co-create value propositions that emphasize quality of life improvements and efficient use of health system resources, which will position product portfolios for sustained adoption.

A clear and transparent mixed-methods research methodology combining expert interviews, regulatory review, and evidence triangulation to ensure rigorous, actionable insights

This research adopts a mixed-methods approach combining qualitative interviews with clinicians, procurement leaders, and payers, along with secondary review of regulatory guidance, clinical literature, and policy developments. The methodology emphasizes triangulation: triangulating expert perspectives against procedural guidelines and publicly available clinical evidence to identify convergent themes and areas of divergence. Data validation included cross-referencing procedural trends and technology adoption signals to ensure internal consistency and practical relevance.

Throughout the research process, emphasis was placed on transparency of assumptions and reproducibility of analytic steps. Stakeholder interviews were conducted across care settings and geographies to capture a representative set of perspectives, and methodological limitations were documented to highlight areas where additional primary research could strengthen inference. This approach supports confident, actionable insights while acknowledging the evolving nature of clinical practice and regulatory environments.

Concluding synthesis emphasizing how clinical innovation, supply chain resilience, and evidence alignment will determine long-term success in fibroid device markets

In conclusion, the uterine fibroid treatment device landscape is transitioning toward less invasive, value-oriented care pathways that prioritize patient recovery, fertility preservation, and efficient use of healthcare resources. Technological innovation and procedural refinement have expanded therapeutic choices, creating both opportunities and complexity for clinicians and purchasers. Market success will favor organizations that align clinical evidence generation with pragmatic value propositions and adaptive commercial strategies.

Moreover, external factors such as trade policies and regional heterogeneity in regulatory and reimbursement systems impose operational considerations that cannot be ignored. Stakeholders that proactively address supply chain resilience, invest in clinician training, and engage payers with clear outcome-focused data will be best positioned to capture opportunity and deliver sustained clinical impact. Continued collaboration across manufacturers, clinicians, and health systems will remain essential to translate innovation into improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Uterine Fibroid Treatment Device Market, by Product Type

  • 8.1. High Intensity Focused Ultrasound
  • 8.2. Hysterectomy
    • 8.2.1. Abdominal
    • 8.2.2. Laparoscopic
    • 8.2.3. Vaginal
  • 8.3. Myomectomy
    • 8.3.1. Hysteroscopic
    • 8.3.2. Laparoscopic
    • 8.3.3. Open
  • 8.4. Radiofrequency Ablation
  • 8.5. Uterine Artery Embolization

9. Uterine Fibroid Treatment Device Market, by Technology

  • 9.1. Cryoablation
  • 9.2. High Intensity Focused Ultrasound
  • 9.3. Microwave Ablation
  • 9.4. Radiofrequency Ablation

10. Uterine Fibroid Treatment Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Specialized Fibroid Centers

11. Uterine Fibroid Treatment Device Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Uterine Fibroid Treatment Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Uterine Fibroid Treatment Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Uterine Fibroid Treatment Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Uterine Fibroid Treatment Device Market

16. China Uterine Fibroid Treatment Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acessa Health Inc.
  • 17.7. AngioDynamics, Inc.
  • 17.8. Boston Scientific Corporation
  • 17.9. Cook Group Incorporated
  • 17.10. CooperSurgical, Inc.
  • 17.11. Gynesonics, Inc.
  • 17.12. Hologic, Inc.
  • 17.13. INSIGHTEC Ltd.
  • 17.14. Karl Storz SE & Co. KG
  • 17.15. Medtronic plc
  • 17.16. Merit Medical Systems, Inc.
  • 17.17. Minerva Surgical, Inc.
  • 17.18. Olympus Corporation
  • 17.19. Profound Medical Corp.
  • 17.20. Richard Wolf GmbH
  • 17.21. SonaCare Medical, LLC
  • 17.22. Varian Medical Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 139. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 160. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)